DARWIN AG Logo

DARWIN AG

7V0 | MU

Overview

Corporate Details

ISIN(s):
DE000A3C35W0
LEI:
391200XJOD6U0EW7OE14
Country:
Germany
Address:
Brienner Str. 7, 80333 München
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

DARWIN AG is a biotechnology company that develops personalized products, services, and therapies based on unique biological data. The company integrates advanced laboratory analysis of the human genome and metabolome with proprietary artificial intelligence platforms to gain deep insights into individual health. Its core offerings include personalized supplements and cosmetics, genetic reports with actionable health plans, and services for the optimization of medical therapies, including IVF and personalized drug development. Operating as a technology-driven group with multiple brands, DARWIN AG serves both direct-to-consumer (B2C) and business-to-business (B2B) markets, partnering with medical professionals and other companies. The company's unique 'Analyse. Learn. Solve.' approach enables the creation of highly tailored solutions at an industrial scale.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for DARWIN AG. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-30 00:00
Annual Report
Datum:30.07.2025
German 384.3 KB
2024-10-01 00:00
Annual Report
Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 255.3 KB
2024-09-10 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 69.8 KB
2023-09-20 00:00
Board/Management Information
Ergänzung der Veröffentlichung vom 05.01.2023
German 8.2 KB
2023-08-11 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 56.9 KB
2023-06-06 00:00
Annual / Quarterly Financial Statement
Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 217.2 KB
2023-03-21 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 15.03.2021 bis zum 31.12.2021
German 44.0 KB
2023-01-05 00:00
Annual / Quarterly Financial Statement
Ergänzt am 20.09.2023
German 169.9 KB

Automate Your Workflow. Get a real-time feed of all DARWIN AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for DARWIN AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Purple Biotech Ltd. Logo
Develops first-in-class cancer therapies targeting tumor immune evasion and drug resistance.
Israel PPBT
Develops uncopiable atomic fingerprints for anti-counterfeiting, verifiable by smartphone.
United Kingdom N/A
QUANTUM BLOCKCHAIN TECHNOLOGIES PLC Logo
R&D firm using AI and quantum computing to create efficient technologies for Bitcoin mining.
United Kingdom QBT
Quantum Genomics Logo
Develops digital twin solutions to simulate drug effects and personalize treatments.
France ALQGC
QUIA PHARMA AB Logo
Develops enhanced drugs using a patented, releasable pegylation drug delivery platform.
Sweden QUIA
Read Gene Spolka Akcyjna Logo
Develops DNA tests to identify genetic cancer risk for early detection and prevention.
Poland RDG
RELIEF Therapeutics Holding AG Logo
Developing and commercializing novel therapies for rare and ultra-rare diseases.
Switzerland RLF
Respiratorius AB Logo
Developing innovative drug candidates to enhance standard therapies for aggressive cancers.
Sweden RESP
ROQUEFORT THERAPEUTICS PLC Logo
Developing novel immuno-oncology medicines for hard-to-treat, resistant cancers.
United Kingdom ROQ
United States of America N/A